Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts
Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 41; no. 1; pp. 1 - 23 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
20.08.2022
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment. |
---|---|
AbstractList | The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored.BACKGROUNDThe progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored.NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model.METHODSNPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model.NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature.RESULTSNPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature.EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.CONCLUSIONEBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment. Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment. Abstract Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment. |
ArticleNumber | 254 |
Author | Tsang, Ngan-Ming Chang, Kai-Ping Lee, Po-Ju Sui, Yun-Hua Huang, Chen-Han Liu, Shu-Chen Liu, Tzu-Tung Lin, Ting-Yi |
Author_xml | – sequence: 1 givenname: Po-Ju surname: Lee fullname: Lee, Po-Ju – sequence: 2 givenname: Yun-Hua surname: Sui fullname: Sui, Yun-Hua – sequence: 3 givenname: Tzu-Tung surname: Liu fullname: Liu, Tzu-Tung – sequence: 4 givenname: Ngan-Ming surname: Tsang fullname: Tsang, Ngan-Ming – sequence: 5 givenname: Chen-Han surname: Huang fullname: Huang, Chen-Han – sequence: 6 givenname: Ting-Yi surname: Lin fullname: Lin, Ting-Yi – sequence: 7 givenname: Kai-Ping surname: Chang fullname: Chang, Kai-Ping – sequence: 8 givenname: Shu-Chen surname: Liu fullname: Liu, Shu-Chen |
BookMark | eNp9Us1u1DAQtlARbRdegFMkLlxC7fgn8QVpqVqoVIke4MDJcmwn61ViB9tZldfhDXgRnglnUyTaAwfL1sz3feOZ-c7BifPOAPAawXcINewiIgwJK2FV5UMoK-kzcIbq_OCcsZN_3qfgPMY9hAxxxF-AU0x5wzDjZ-Dn1RSTsa78IEMoDjbIoZiC17NKpfIuSeus6wtz76MfTVxyo0-m6GwbfLSxkE4XTkY_7WT44XqT-UoGZZ0f5YLug4nRelekXfBzvyukSvYg0xLyXfFte4currd3v38V0fZODks161b9dpAxxZfgeSeHaF493Bvw9frqy-Wn8vbzx5vL7W2pSI1TyQypatVKRnnbIGK04rBrGalhzVAFYW0gpqTjRmvaorZpJOWG0w4SaThkEm_AzaqrvdyLKdgxdyS8tOIY8KEXMiSrBiMQww00GmleY1JxzTXRNcEQYgSpPmq9X7WmuR3zV4xLebKPRB9nnN2J3h8Ex7zCFcoCbx8Egv8-m5jEaKMywyCd8XMUVQ1Jw2qU0Rvw5gl07-eQR7mgEM2CDNKMalaUynuLwXRC2XRcQ65vB4GgWEwlVlOJbCpxNJVYqNUT6t8-_kP6A-9Y1Ac |
CitedBy_id | crossref_primary_10_1007_s13402_023_00888_5 crossref_primary_10_2967_jnumed_123_266183 crossref_primary_10_1093_nargab_lqad106 crossref_primary_10_1186_s12575_024_00245_2 crossref_primary_10_1093_pcmedi_pbae018 crossref_primary_10_1016_j_canlet_2023_216225 crossref_primary_10_1016_j_heliyon_2024_e30808 crossref_primary_10_1186_s12943_024_01932_0 crossref_primary_10_1186_s12935_022_02784_8 crossref_primary_10_25259_Cytojournal_149_2024 crossref_primary_10_1016_j_intimp_2024_114011 crossref_primary_10_3390_medicina59010002 crossref_primary_10_1016_j_gendis_2023_101117 crossref_primary_10_1016_j_jdermsci_2023_12_004 crossref_primary_10_3389_fimmu_2024_1377722 crossref_primary_10_1016_j_canlet_2024_217244 crossref_primary_10_1186_s12957_024_03441_2 crossref_primary_10_3390_cancers16050919 crossref_primary_10_3389_fimmu_2025_1560897 crossref_primary_10_1038_s41389_025_00549_2 crossref_primary_10_1016_j_virusres_2024_199352 crossref_primary_10_1186_s12967_024_06064_z |
Cites_doi | 10.1084/jem.20140692 10.1016/S1040-8428(02)00115-4 10.1186/1471-2105-14-7 10.1038/nrc1452 10.1038/nrm.2017.87 10.1182/blood-2008-02-142596 10.1093/emboj/19.24.6778 10.1038/s41467-018-07660-6 10.1038/ncb3336 10.1038/s41422-020-0374-x 10.3390/ijms19113674 10.1172/JCI88759 10.1172/JCI63428 10.1016/S1097-2765(02)00776-1 10.3390/pathogens7020040 10.1074/mcp.M900381-MCP200 10.1073/pnas.1220998110 10.1002/ijc.22334 10.1158/0008-5472.CAN-10-1722 10.1038/ncomms15321 10.1006/scbi.2001.0412 10.1038/nrc3876 10.1002/mc.23150 10.1038/ncb2303 10.1016/j.semcancer.2008.10.004 10.1016/j.intimp.2009.01.015 10.1073/pnas.0506580102 10.1016/j.semcancer.2008.10.002 10.1101/gad.173435.111 10.1016/j.semcancer.2013.12.009 10.1158/1078-0432.CCR-06-2945 10.1016/j.virol.2010.06.037 10.1038/onc.2008.250 10.1016/j.ccr.2014.03.007 10.3390/cancers10040106 10.1111/cas.13473 10.2147/CMAR.S167071 10.1038/ncb1725 10.1016/j.jhep.2015.04.011 10.1016/j.xinn.2021.100141 10.1073/pnas.1014194107 10.1158/1535-7163.MCT-11-0340 10.1016/j.canlet.2013.05.012 10.1038/onc.2014.66 |
ContentType | Journal Article |
Copyright | 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). The Author(s) 2022 |
Copyright_xml | – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). – notice: The Author(s) 2022 |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s13046-022-02456-5 |
DatabaseName | CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (New) ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 23 |
ExternalDocumentID | oai_doaj_org_article_16380ed1d973429d9d4d743003105d6a PMC9392321 10_1186_s13046_022_02456_5 |
GeographicLocations | Taiwan |
GeographicLocations_xml | – name: Taiwan |
GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c473t-6e427cba659b814edc90fb64707612007e0354f9edd5b1b88a59e95f04ae906a3 |
IEDL.DBID | M48 |
ISSN | 1756-9966 0392-9078 |
IngestDate | Wed Aug 27 01:25:17 EDT 2025 Thu Aug 21 17:40:49 EDT 2025 Fri Jul 11 04:08:17 EDT 2025 Fri Jul 25 08:08:47 EDT 2025 Thu Apr 24 22:57:23 EDT 2025 Tue Jul 01 02:26:48 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c473t-6e427cba659b814edc90fb64707612007e0354f9edd5b1b88a59e95f04ae906a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://doaj.org/article/16380ed1d973429d9d4d743003105d6a |
PMID | 35986369 |
PQID | 2715392605 |
PQPubID | 105475 |
PageCount | 23 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_16380ed1d973429d9d4d743003105d6a pubmedcentral_primary_oai_pubmedcentral_nih_gov_9392321 proquest_miscellaneous_2704867192 proquest_journals_2715392605 crossref_citationtrail_10_1186_s13046_022_02456_5 crossref_primary_10_1186_s13046_022_02456_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-08-20 |
PublicationDateYYYYMMDD | 2022-08-20 |
PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationYear | 2022 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | P Kucharzewska (2456_CR7) 2013; 110 T Ogino (2456_CR18) 2007; 120 A Elosegui-Artola (2456_CR40) 2016; 18 S Hänzelmann (2456_CR35) 2013; 14 I Mannaerts (2456_CR33) 2015; 63 JM Middeldorp (2456_CR13) 2008; 18 T Moroishi (2456_CR47) 2015; 15 2456_CR26 F Liu (2456_CR32) 2015; 308 YP Chen (2456_CR48) 2020; 30 H Kanegane (2456_CR17) 2002; 44 S Basu (2456_CR30) 2003; 11 2456_CR44 YM Chang (2456_CR45) 2008; 27 F Kanai (2456_CR31) 2000; 19 K Al-Nedawi (2456_CR6) 2008; 10 2456_CR27 B Zhao (2456_CR41) 2012; 26 HC Lai (2456_CR15) 2010; 405 K Houali (2456_CR24) 2007; 13 D Ohlund (2456_CR2) 2014; 211 G Nardone (2456_CR39) 2017; 8 Y Yu (2456_CR3) 2018; 10 S Pai (2456_CR14) 2001; 11 SC Liu (2456_CR19) 2013; 123 S Wang (2456_CR5) 2014; 2014 J Klibi (2456_CR25) 2009; 113 DG Meckes Jr (2456_CR21) 2010; 107 J Li (2456_CR16) 2009; 9 O De Wever (2456_CR1) 2014; 25 C Munz (2456_CR12) 2008; 18 B Zhao (2456_CR29) 2011; 13 2456_CR36 H Zheng (2456_CR20) 2007; 4 T Yoshizaki (2456_CR28) 2018; 109 YH Zhu (2456_CR4) 2020; 59 T Panciera (2456_CR42) 2017; 18 V Ramjee (2456_CR43) 2017; 127 WN Brennen (2456_CR46) 2012; 11 W Zhou (2456_CR9) 2014; 25 LS Young (2456_CR11) 2004; 4 M Aga (2456_CR23) 2014; 33 2456_CR38 CT Lin (2456_CR34) 1993; 68 A Subramanian (2456_CR37) 2005; 102 JE Park (2456_CR8) 2010; 9 J Webber (2456_CR10) 2010; 70 A Canitano (2456_CR22) 2013; 337 |
References_xml | – volume: 4 start-page: 185 year: 2007 ident: 2456_CR20 publication-title: Cell Mol Immunol – volume: 211 start-page: 1503 year: 2014 ident: 2456_CR2 publication-title: J Exp Med doi: 10.1084/jem.20140692 – volume: 44 start-page: 239 year: 2002 ident: 2456_CR17 publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(02)00115-4 – volume: 14 start-page: 7 year: 2013 ident: 2456_CR35 publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-14-7 – volume: 4 start-page: 757 year: 2004 ident: 2456_CR11 publication-title: Nat Rev Cancer doi: 10.1038/nrc1452 – volume: 18 start-page: 758 year: 2017 ident: 2456_CR42 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm.2017.87 – volume: 113 start-page: 1957 year: 2009 ident: 2456_CR25 publication-title: Blood doi: 10.1182/blood-2008-02-142596 – volume: 19 start-page: 6778 year: 2000 ident: 2456_CR31 publication-title: EMBO J doi: 10.1093/emboj/19.24.6778 – ident: 2456_CR38 doi: 10.1038/s41467-018-07660-6 – volume: 18 start-page: 540 year: 2016 ident: 2456_CR40 publication-title: Nat Cell Biol doi: 10.1038/ncb3336 – volume: 30 start-page: 1024 year: 2020 ident: 2456_CR48 publication-title: Cell Res doi: 10.1038/s41422-020-0374-x – ident: 2456_CR44 doi: 10.3390/ijms19113674 – volume: 127 start-page: 899 year: 2017 ident: 2456_CR43 publication-title: J Clin Invest doi: 10.1172/JCI88759 – volume: 123 start-page: 5269 year: 2013 ident: 2456_CR19 publication-title: J Clin Invest doi: 10.1172/JCI63428 – volume: 11 start-page: 11 year: 2003 ident: 2456_CR30 publication-title: Mol Cell doi: 10.1016/S1097-2765(02)00776-1 – ident: 2456_CR27 doi: 10.3390/pathogens7020040 – volume: 9 start-page: 1085 year: 2010 ident: 2456_CR8 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M900381-MCP200 – volume: 110 start-page: 7312 year: 2013 ident: 2456_CR7 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1220998110 – volume: 308 start-page: L344 year: 2015 ident: 2456_CR32 publication-title: Am J Phys Lung Cell Mol Phys – volume: 120 start-page: 2401 year: 2007 ident: 2456_CR18 publication-title: Int J Cancer doi: 10.1002/ijc.22334 – volume: 70 start-page: 9621 year: 2010 ident: 2456_CR10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1722 – volume: 8 start-page: 15321 year: 2017 ident: 2456_CR39 publication-title: Nat Commun doi: 10.1038/ncomms15321 – volume: 2014 start-page: 507353 year: 2014 ident: 2456_CR5 publication-title: Biomed Res Int – volume: 11 start-page: 455 year: 2001 ident: 2456_CR14 publication-title: Semin Cancer Biol doi: 10.1006/scbi.2001.0412 – volume: 15 start-page: 73 year: 2015 ident: 2456_CR47 publication-title: Nat Rev Cancer doi: 10.1038/nrc3876 – volume: 59 start-page: 265 year: 2020 ident: 2456_CR4 publication-title: Mol Carcinog doi: 10.1002/mc.23150 – volume: 13 start-page: 877 year: 2011 ident: 2456_CR29 publication-title: Nat Cell Biol doi: 10.1038/ncb2303 – volume: 68 start-page: 716 year: 1993 ident: 2456_CR34 publication-title: Lab Investig – volume: 18 start-page: 388 year: 2008 ident: 2456_CR13 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.10.004 – volume: 9 start-page: 590 year: 2009 ident: 2456_CR16 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2009.01.015 – volume: 102 start-page: 15545 year: 2005 ident: 2456_CR37 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0506580102 – volume: 18 start-page: 381 year: 2008 ident: 2456_CR12 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.10.002 – volume: 26 start-page: 54 year: 2012 ident: 2456_CR41 publication-title: Genes Dev doi: 10.1101/gad.173435.111 – volume: 25 start-page: 33 year: 2014 ident: 2456_CR1 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2013.12.009 – volume: 13 start-page: 4993 year: 2007 ident: 2456_CR24 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2945 – volume: 405 start-page: 464 year: 2010 ident: 2456_CR15 publication-title: Virology doi: 10.1016/j.virol.2010.06.037 – volume: 27 start-page: 6365 year: 2008 ident: 2456_CR45 publication-title: Oncogene doi: 10.1038/onc.2008.250 – volume: 25 start-page: 501 year: 2014 ident: 2456_CR9 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.03.007 – ident: 2456_CR26 doi: 10.3390/cancers10040106 – volume: 109 start-page: 272 year: 2018 ident: 2456_CR28 publication-title: Cancer Sci doi: 10.1111/cas.13473 – volume: 10 start-page: 1935 year: 2018 ident: 2456_CR3 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S167071 – volume: 10 start-page: 619 year: 2008 ident: 2456_CR6 publication-title: Nat Cell Biol doi: 10.1038/ncb1725 – volume: 63 start-page: 679 year: 2015 ident: 2456_CR33 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.04.011 – ident: 2456_CR36 doi: 10.1016/j.xinn.2021.100141 – volume: 107 start-page: 20370 year: 2010 ident: 2456_CR21 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1014194107 – volume: 11 start-page: 257 year: 2012 ident: 2456_CR46 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-11-0340 – volume: 337 start-page: 193 year: 2013 ident: 2456_CR22 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.05.012 – volume: 33 start-page: 4613 year: 2014 ident: 2456_CR23 publication-title: Oncogene doi: 10.1038/onc.2014.66 |
SSID | ssj0061919 |
Score | 2.447226 |
Snippet | Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the... The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the... Abstract Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1 |
SubjectTerms | Biopsy Cancer Collagen Cytokines EBV Epstein-Barr virus Exosome Experiments Fibroblast Fibroblasts Laboratory animals Metastasis MicroRNAs Nasopharyngeal carcinoma NPC Proteins Throat cancer Vascular endothelial growth factor |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4lcECjISN2RtnNhOfNyiriqkoh6oVE6WHTuwUuusNlsJXoc34EV4Jmbs7Kq5wIVr7FiJZ-z5xjP-hpB3GMzzQZfMw_7IkBGcaV11DGxPKftWe5vuVp1_UmeX4uOVvLpT6gtzwjI9cJ64BeKFMnjudVPD3um1Fx6sXqK0lF4laAQ2b-9M5T0YvAKu91dkWrUYOQYAGWauY6hRMTkzQ4mtfwYx5wmSdyzO6hF5OEFFusyf-JjcC_EJuX8-BcOfkp-nmxFrVbITu91STNa9pptM4MowAz3XfqDh-zAON2HENpBLoD14yMO4HqmNnkaLdQzs9kf8CpCRdlhaKA43lqbErUzaQadiPhQvQeQjXDr09Mvygi9Wy4vfvyhmgVi82E7XMY_vAJXvxmfkcnX6-cMZm0ousE409Y6pIKqmc1ZJ7VouYAZ02TslGjzuwGPNUNZS9Dp4Lx13bWulDlr2pbAgcGXr5-QoDjG8IJTXXtWVtpULjehLB0CothLpZ_pO-yoUhO8lYLqJjxzLYlyb5Je0ymSpGZCaSVIzsiDvD-9sMhvHX3ufoGAPPZFJOz0A_TKTfpl_6VdBjvdqYablPZqqAUOh0RUsyNtDMyxMjLbYGIZb7JPYDAFBF6SZqdPsg-Ytcf0tUXxrGL2u-Mv_8QevyIMqaT5uicfkaLe9Da8BSe3cm7Ro_gAShhzC priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgLKn8iUJCRuCFr82cnPlVb1FWFVNQDlZaT5cROWam1l2Qr0dfpG_AifabOON6FXHpde7OrzIz9eWb8fYR8xmKesTJlBtZHhozgTMq8ZbD3pLyrpdHhbtXpd3FyXn5b8mVMuA2xrXK7JoaF2vgWc-SzvILYlIi-D9e_GapGYXU1Smg8Jk-Qugxbuqrl7sAFZ4Mg7AE7pGCI67eXZmoxGzIsCTLsZcfio2B8sjEF_v4J6Jy2TP63By32yfMIHul8tPYL8si6l-TpaSyPvyK3x-sB1SvZke57iu27l3Q9Uroy7Ekf1SCo_eMHf2UHHANLWdrBmdkPq4FqZ6jTqGyg-xt3ASCStig25PyVpqGVa6TxoFHeh-K1iDGpS31Hf87Pstlifnb3l2JfiMar7nTlxuc3gNM3w2tyvjj-8fWERREG1pZVsWHClnnVNlpw2dRZCW9Apl0jygoTIJjotGnBy05aY3iTNXWtubSSd2mpwQWELt6QPeedfUtoVhhR5FLnja3KLm0AGhWaIyFN10qT24RkWwuoNjKUo1DGpQonlVqo0WoKrKaC1RRPyJfdd9YjP8eDs4_QsLuZyK0dPvD9hYqhqhChptZkRlYF7NZGmtIAzgokqtwInZCDrVuoGPCD-ueeCfm0G4ZQxfqLdtZf45zAbwiYOiHVxJ0mf2g64la_Aum3hKcXefbu4R9_T57lwadx-Tsge5v-2n4A1LRpPobQuAfz2Reg priority: 102 providerName: ProQuest |
Title | Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts |
URI | https://www.proquest.com/docview/2715392605 https://www.proquest.com/docview/2704867192 https://pubmed.ncbi.nlm.nih.gov/PMC9392321 https://doaj.org/article/16380ed1d973429d9d4d743003105d6a |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3bitswEBV7gdKX0it1uw0q9K2o65sk66GUpCQshSxhaSDti5EteTeQtVM7C7u_0z_oj_SbOiPboYal9CUPkSKCZ8ZzpBmdQ8g7LOYZq3xm4P3IkBGcKRXmDHKPz4tEGe3uVs3Pxdky_rLiqwPSyx11D7C5d2uHelLLevPh9sfdJwj4jy7gE3HaBFjeY9iXjoVEwfghOYbMJDFQ5_G-qgB7BSf0ARlTMMT5_SWae9cYJCrH5z8AocMWyr9y0uwxedSBSTpurf-EHNjyKXkw78rlz8jP6bZBNUs20XVNsZ13Q7ctxSvDHvVWHYLa26qprm2DY2A5SwvYQ1fNuqG6NLTUqHSg67vyEkAlzVF8qKyuNXWtXS2tB-3kfihek2gPeWlV0G_jRXA6Gy9-_6LYJ6Lx6jtdl-36GeD2XfOcLGfTr5_PWCfKwPJYRjsmbBzKPNOCqywJYngCyi8yEUs8EMGDT-tHPC6UNYZnQZYkmiureOHHGlxC6OgFOSqr0r4kNIiMiEKlw8zKuPAzgEqR5khQU-TKhNYjQW-BNO8Yy1E4Y5O6nUsi0tZqKVgtdVZLuUfe73-zbfk6_jl7gobdz0SubfdFVV-mXeimiFh9awKjZATZ2ygTG8BdjlSVG6E9ctK7Rdr7bxpKSCUKN4seebsfhtDFeowubXWDcxzfIWBsj8iBOw3-0HCkXF85EnAFq0dh8Oo_Vn9NHobOsfGdeEKOdvWNfQNQapeNyKFcyRE5nkzPFxcjdyAxcjEDnxeT738AWLMhWg |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviL-iMMBI8ISs5p-d-AGhFlp1bK0qtEnjyTixMyptSWk6wb4OHwCJL8Jn4s5JCnnZ215rx2l05_Od7-73I-QVJvOMlR4zYB8ZIoIzKYOMwdnj8TyRRrveqtlcTI-jjyf8ZIf8anthsKyytYnOUJsywzvyQRDD3pTofb9bfWPIGoXZ1ZZCo1aLA3v5HUK26u3-B5Dv6yCYjI_eT1nDKsCyKA43TNgoiLNUCy7TxI-syaSXpyKKMaLHmzvrhTzKpTWGp36aJJpLK3nuRRq-SegQ1r1BdqMQQpke2R2N54tPre2HaMRRicCZLBhGEm2bTiIGlY9JSIbV85juFIx3jkLHGNBxc7tFmv-depO75E7jrtJhrV_3yI4t7pObsyYh_4D8HK8q5MtkI71eUywYPqOrGkSWYRV8zT9B7Y-yKs9thWOgG5bmEKWX1bKiujC00MiloNeXxSm4rTRDeqOiPNfUFY_VwCG0IRSi2IhRXyPTMqefhwt_MBku_vymWImisbmeLot6_RQig031kBxfi4AekV5RFvYxoX5oRBhIHaQ2jnIvBWcs1BwhcPJMmsD2id9KQGUNJjpSc5wpFxslQtVSUyA15aSmeJ-82T6zqhFBrpw9QsFuZyKat_uhXJ-qxjgo9Ik9a3wj4xD8AyNNZMCzc7Ct3AjdJ3utWqjGxFTq34bok5fbYTAOmPHRhS0vcI5DVAQvvk_ijjp1_lB3pFh-dTDjElYPA__J1S9_QW5Nj2aH6nB_fvCU3A6cfqPx3SO9zfrCPgOfbZM-bzYKJV-ue2_-BbaHVV0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epstein-Barr+viral+product-containing+exosomes+promote+fibrosis+and+nasopharyngeal+carcinoma+progression+through+activation+of+YAP1%2FFAP%CE%B1+signaling+in+fibroblasts&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Lee%2C+Po-Ju&rft.au=Sui%2C+Yun-Hua&rft.au=Liu%2C+Tzu-Tung&rft.au=Tsang%2C+Ngan-Ming&rft.date=2022-08-20&rft.issn=1756-9966&rft.eissn=1756-9966&rft.volume=41&rft.issue=1&rft.spage=254&rft_id=info:doi/10.1186%2Fs13046-022-02456-5&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |